Bernard Coulie Pliant Therapeutics, Inc. (PLRX) insider trading activity

Bernard Coulie is President and CEO of PLIANT THERAPEUTICS, INC.. Currently has a direct ownership of 593,017 shares of PLRX, which is worth approximately $931,036. The most recent transaction as insider was on Jan 25, 2023, when has been sold 146,300 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 593K

0% 3M change

22.79% 12M change

Total Value Held $931,036

Bernard Coulie Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 25 2023	BUY Grant, award, or other acquisition	-	146,300 Added 37.86%	240,112 Common Stock
Jan 25 2023	BUY Exercise of conversion of derivative security	$31,200 $2.08 p/Share	15,000 Added 12.12%	108,812 Common Stock
Jan 24 2023	SELL Open market or private sale	$463,350 $30.89 p/Share	15,000 Reduced 13.79%	93,812 Common Stock
Jan 24 2023	BUY Exercise of conversion of derivative security	$31,200 $2.08 p/Share	15,000 Added 12.12%	108,812 Common Stock
Jan 23 2023	SELL Open market or private sale	$514,800 $34.32 p/Share	15,000 Reduced 13.79%	93,812 Common Stock
Jan 23 2023	BUY Exercise of conversion of derivative security	$31,200 $2.08 p/Share	15,000 Added 12.12%	108,812 Common Stock
Jan 09 2023	SELL Open market or private sale	$95,850 $19.17 p/Share	5,000 Reduced 5.06%	93,812 Common Stock
Jan 09 2023	BUY Exercise of conversion of derivative security	$10,400 $2.08 p/Share	5,000 Added 4.82%	98,812 Common Stock
Jan 06 2023	SELL Open market or private sale	$285,600 $19.04 p/Share	15,000 Reduced 13.79%	93,812 Common Stock
Jan 06 2023	BUY Exercise of conversion of derivative security	$31,200 $2.08 p/Share	15,000 Added 12.12%	108,812 Common Stock
Jan 04 2023	SELL Open market or private sale	$285,900 $19.06 p/Share	15,000 Reduced 13.79%	93,812 Common Stock
Jan 04 2023	BUY Exercise of conversion of derivative security	$31,200 $2.08 p/Share	15,000 Added 12.12%	108,812 Common Stock
Jan 03 2023	SELL Open market or private sale	$289,950 $19.33 p/Share	15,000 Reduced 13.79%	93,812 Common Stock
Jan 03 2023	BUY Exercise of conversion of derivative security	$31,200 $2.08 p/Share	15,000 Added 12.12%	108,812 Common Stock
Dec 20 2022	SELL Open market or private sale	$653,449 $19.1 p/Share	34,212 Reduced 26.72%	93,812 Common Stock
Dec 19 2022	BUY Grant, award, or other acquisition	-	68,751 Added 34.94%	128,024 Common Stock
Sep 12 2022	SELL Open market or private sale	$281,795 $22.54 p/Share	12,502 Reduced 17.42%	59,273 Common Stock
Sep 12 2022	BUY Exercise of conversion of derivative security	$26,004 $2.08 p/Share	12,502 Added 14.83%	71,775 Common Stock
Jul 12 2022	SELL Open market or private sale	$281,205 $22.5 p/Share	12,498 Reduced 17.41%	59,273 Common Stock
Jul 12 2022	BUY Exercise of conversion of derivative security	$25,996 $2.08 p/Share	12,498 Added 14.83%	71,771 Common Stock
Jul 11 2022	SELL Open market or private sale	$337,500 $22.5 p/Share	15,000 Reduced 20.2%	59,273 Common Stock
Jul 11 2022	BUY Exercise of conversion of derivative security	$31,200 $2.08 p/Share	15,000 Added 16.8%	74,273 Common Stock
Apr 13 2021	BUY Exercise of conversion of derivative security	$12,480 $2.08 p/Share	6,000 Added 9.86%	54,840 Common Stock

Also insider at

SQZ

SQZ Biotechnologies Co Healthcare

Director

SEPN

Septerna, Inc.

Bernard Coulie

President and CEO

South San Francisco, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells PLRX shares.

Notify only if

Value

Insider Trading

Get notified when an Pliant Therapeutics, Inc. insider buys or sells PLRX shares.

Notify only if

Operation

Value

Type

News

Receive news related to PLIANT THERAPEUTICS, INC.

Track Activities on PLRX

Account